Michael Bennett, Corinne Fantz, and more
The American Association for Clinical Chemistry announced that Michael Bennett has been elected president-elect. He will start serving on AACC's board in that position starting in January and will become its president in 2017. Bennett is a professor of pathology and laboratory medicine at the University of Pennsylvania and chief of laboratory medicine and director of clinical chemistry and the metabolic disease laboratory at Children's Hospital of Philadelphia. He is currently AACC's treasurer, chair-elect of the association's proteomics and metabolomics division, and is a past president of AACC's academy, the National academy of Clinical Biochemistry.
Additionally, AACC elected a new treasurer and two new board members, who will start their three-year terms at the start of 2016. Corinne Fantz was elected the treasurer. She is director of scientific affairs, point-of-care testing at Roche Diagnostics. Linnea Baudhuin and William Clarke were elected to AACC's board. Baudhuin is an associate professor of laboratory medicine and pathology at the Mayo Clinic, where she also is co-director of the Personalized Genomics Laboratory, the Clinical Genomics Sequencing Laboratory, and Cardiovascular Laboratory. Clarke is an associate professor of pathology and director of point-of-care testing and clinical toxicology at Johns Hopkins Hospital.
Alere Senior Vice President of Finance David Teitel resigned from the firm on Sept. 30, Alere said in a document filed with the US Securities and Exchange Commission. No reason was given for his resignation. Earlier this year, Alere said that Teitel would be transitioning from his role as CFO and treasurer at the firm into a new role. He joined Alere in 2003 as director of finance operations and became vice president of finance the following year.
Frederic Walder is relinquishing his title and responsibilities as chief operating officer at Fluidigm, effective Oct. 12, the company said in a document filed with the US Securities and Exchange Commission. He also informed the firm that he would be taking a leave of absence for up to three months to address personal family matters.
MetaMark Genetics named Peter Maimonis senior vice president and chief science officer, effective Oct. 7. He has held senior level postitions at Ciba-Corning, Chiron Diagnostics, Bayer Diagnostics, Decision Biomarkers, and On-Q-ity. Most recently, he was VP of biomarker development at Biothera.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.